Drug companies must be open about using doctors as consultants, new code of practice demandsBMJ 2008; 336 doi: http://dx.doi.org/10.1136/bmj.39581.584815.DB (Published 15 May 2008) Cite this as: BMJ 2008;336:1095
- Owen Dyer
The way that drug companies hire and reward doctors for consultancy work is to be regulated in the United Kingdom for the first time under new rules laid down by the British drug industry’s trade association.
The revised code of practice from the Association of the British Pharmaceutical Industry bars drug companies from offering “token consultancy arrangements” that are used “to justify compensating health professionals.”
Consultancy work must be covered by a written contract that lays out the services involved, it says, and remuneration should reflect fair market value. Companies should not engage more consultants than they need, says the new …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial